WinRevair’s Phase 3 HYPERION trial was stopped early for efficacy, with positive top-line results announced in the month ...

Adjusted EBITDA (Q4): Adjusted EBITDA loss of $316,000 for Q4 FY2025, substantially narrowed from a $1.7 million adjusted ...